Experienced in Teratoma of the Mediastinum

Salvatore G. Grisanti

Ratzeburger Allee 160, 
Luebeck, SH, DE 
Experienced in Teratoma of the Mediastinum
Ratzeburger Allee 160, 
Luebeck, SH, DE 
OverviewLocationsClinical Research

Overview

Salvatore Grisanti practices in Luebeck, Germany. Mr. Grisanti is rated as an Experienced expert by MediFind in the treatment of Teratoma of the Mediastinum. His top areas of expertise are Adrenocortical Carcinoma, Adrenal Cancer, Uveal Melanoma, Vitrectomy, and Trabeculectomy.

His clinical research consists of co-authoring 285 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Teratoma of the Mediastinum.

Gender
Male

Locations

Ratzeburger Allee 160, Luebeck, SH 23538, Germany
Other Locations
Ratzeburger Allee 160, Luebeck, SH 23562, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Randomized, Phase 2, Double-blind Study to Evaluate the Efficacy of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Metastatic Non-Squamous Non-Small Cell Lung Cancer
A Randomized, Phase 2, Double-blind Study to Evaluate the Efficacy of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Metastatic Non-Squamous Non-Small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: August 08, 2025
Intervention Type: Drug
Study Drugs: Dostarlimab, Pembrolizumab, Chemotherapy
Study Phase: Phase 2
A Phase 1/2 Trial of a Novel Therapeutic Vaccine (EO2401) in Combination With Immune Check Point Blockade, for Treatment of Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma
A Phase 1/2 Trial of a Novel Therapeutic Vaccine (EO2401) in Combination With Immune Check Point Blockade, for Treatment of Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma
Enrollment Status: Terminated
Publish Date: November 12, 2024
Intervention Type: Biological
Study Drugs: EO2041, Nivolumab
Study Phase: Phase 1/Phase 2
Early Evaluation of the Brown Glaucoma Implant in Patients Refractory to Drug Therapy in the European Union
Early Evaluation of the Brown Glaucoma Implant in Patients Refractory to Drug Therapy in the European Union
Enrollment Status: Terminated
Publish Date: January 10, 2023
Intervention Type: Device
Study Phase: Not Applicable
A NON-COMMERCIAL, MULTICENTER, RANDOMIZED, TWO-ARMED, OPEN-LABEL PHASE III STUDY TO EVALUATE THE ADJUVANT VACCINATION WITH TUMOR RNA-LOADED AUTOLOGOUS DENDRITIC CELLS VERSUS OBSERVATION OF PATIENTS WITH RESECTED MONOSOMY 3 UVEAL MELANOMA
A NON-COMMERCIAL, MULTICENTER, RANDOMIZED, TWO-ARMED, OPEN-LABEL PHASE III STUDY TO EVALUATE THE ADJUVANT VACCINATION WITH TUMOR RNA-LOADED AUTOLOGOUS DENDRITIC CELLS VERSUS OBSERVATION OF PATIENTS WITH RESECTED MONOSOMY 3 UVEAL MELANOMA
Enrollment Status: Unknown
Publish Date: December 02, 2022
Intervention Type: Biological
Study Drug: Autologous Dendritic Cells Loaded with Autologous Tumor RNA
Study Phase: Phase 3
Argus® II Retinal Prosthesis System Post-Market Surveillance Study
Argus® II Retinal Prosthesis System Post-Market Surveillance Study
Enrollment Status: Terminated
Publish Date: May 21, 2020
Argus II Retinal Prosthesis System - Better Vision RP Study
Argus II Retinal Prosthesis System - Better Vision RP Study
Enrollment Status: Withdrawn
Publish Date: June 25, 2019
Intervention Type: Device
Study Phase: Not Applicable
View 5 Less Clinical Trials

283 Total Publications

Advanced-stage ALK-positive non-small-cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS database.
Advanced-stage ALK-positive non-small-cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS database.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: September 16, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Grisanti's expertise for a condition
ConditionClose
View All 12 Advanced Conditions
View All 43 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile